ACONW News and Press, Aclarion Inc. Warrant From 12/19/22

Dr. Uribe is the fourth national KOL to join the Aclarion team this year. Development of this program supports Aclarion’s commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. Broomfield, CO, Dec. 19, 2022 (GLOBE...

BROOMFIELD, CO / ACCESSWIRE / October 25, 2022 / Aclarion, Inc. (NASDAQ:ACON)(NASDAQ:ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low b...

BROOMFIELD, CO / ACCESSWIRE / October 24, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back...

Nociscan utilized within unprecedented NIH HEAL Initiative featured at NASS 2022 Nociscan TM is the first evidence-supported SaaS platform to objectively analyze intradiscal pain Nociscan bridges major diagnostic void between MRI and provocative discography BROOMFIELD, CO / AC...

Aclarion Key Opinion Leader program supports focused strategy of building strong clinical evidence and payer community advocacy to drive adoption of Nociscan TM solution BROOMFIELD, CO / ACCESSWIRE / October 3, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:...

NIH funded Biomarkers for Evaluating Spine Treatments (BEST) Trial launching this quarter BEST to study the role of biomarkers in optimizing the treatment of chronic low back pain Nociscan TM to be commercially active across seven participating major academic medical centers B...

Initial findings from the EVAL study are expected to be released in Q4 2022 Study initiated to assess impact of Nociscan on the cost of care for chronic low back pain (CLBP) patients Promising initial clinical evaluations with 87% of patients treated at discs identified as painful ...

Superior Clinical Outcomes for Nociscan TM Proving to be Durable at Two Years Two Year Results and the Schedule of Future Clinical Trials to be Outlined at the Annual State of Spine Surgery Think Tank 2022 SAN MATEO, CA / ACCESSWIRE / June 22, 2022 / Aclarion, Inc. ("Aclarion" or ...